GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer–Specific Mortality

This study validates the effectiveness of the Genomic Prostate Score® in predicting distant metastases (DM) and prostate cancer–specific mortality (PCSM) over 20 years.

Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer

Insights from this study show that men undergoing active surveillance for their prostate cancer who had a higher Decipher score were more likely to develop aggressive cancer over time. Results conclude that a higher Decipher score might be an indication for tailored active surveillance including frequent prostate biopsies.